Antiviral Therapy for Hepatitis C Virus: Beyond the Standard of Care
AbstractHepatitis C virus (HCV) represents a major health burden, with an estimated 180 million chronically infected individuals worldwide. These patients are at increased risk of developing liver cirrhosis and hepatocellular carcinoma. Infection with HCV is the leading cause of liver transplantation in the Western world. Currently, the standard of care (SoC) consists of pegylated interferon alpha (pegIFN-α) and ribavirin (RBV). However this therapy has a limited efficacy and is associated with serious side effects. Therefore more tolerable, highly potent inhibitors of HCV replication are urgently needed. Both Specifically Targeted Antiviral Therapy for HCV (STAT-C) and inhibitors that are believed to interfere with the host-viral interaction are discussed. View Full-Text
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Delang, L.; Coelmont, L.; Neyts, J. Antiviral Therapy for Hepatitis C Virus: Beyond the Standard of Care. Viruses 2010, 2, 826-866.
Delang L, Coelmont L, Neyts J. Antiviral Therapy for Hepatitis C Virus: Beyond the Standard of Care. Viruses. 2010; 2(4):826-866.Chicago/Turabian Style
Delang, Leen; Coelmont, Lotte; Neyts, Johan. 2010. "Antiviral Therapy for Hepatitis C Virus: Beyond the Standard of Care." Viruses 2, no. 4: 826-866.